It activates two incretin hormone receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1)
While its primarily used to manage blood sugar in individuals with type 2 diabetes, it may also promote weight loss due to its impact on appetite control and reduced calorie intake
Beyond this systemic pathway, preclinical and translational studies suggest several potential joint-relevant mechanisms, including activation of cAMPPKACREB and PI3KAkt signaling, attenuation of NF-B and NLRP3 inflammasome pathways, modulation of macrophage polarization, reduction of endoplasmic-reticulum stress and oxidative stress, inhibition of AGEsRAGE-related inflammatory signaling, and preservation of cartilage extracellular matrix homeostasis (Ryan et al., 2025
GLP-1 medications are a class of drugs specifically aimed at aiding weight management and are used in the treatment of obesity and type-2 diabetes
GLP-1s often lower BP modestly with weight loss
Evaluation of the effects of water volume with dosing and post-dose fasting period on pharmacokinetics of oral semaglutide